Revels, S. L., & Lee, J. M. (2018). Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): Perspective on phase III clinical trials. J Thorac Dis.
Citação norma ChicagoRevels, Sha’Shonda L., and Jay M. Lee. "Anti-angiogenic Therapy in Nonsquamous Non-small Cell Lung Cancer (NSCLC) With Tyrosine Kinase Inhibition (TKI) That Targets the VEGF Receptor (VEGFR): Perspective On Phase III Clinical Trials." J Thorac Dis 2018.
Citação norma MLARevels, Sha’Shonda L., and Jay M. Lee. "Anti-angiogenic Therapy in Nonsquamous Non-small Cell Lung Cancer (NSCLC) With Tyrosine Kinase Inhibition (TKI) That Targets the VEGF Receptor (VEGFR): Perspective On Phase III Clinical Trials." J Thorac Dis 2018.